Skip to main content

Diabetes

  • NDEP updates website with new videos

    WASHINGTON — The Department of Health and Human Services’ National Diabetes Education Program has unveiled a series of videos designed to help people make lifestyle changes and cope with the demands of diabetes.

  • Lilly, BI gear up to present data from studies of diabetes drugs

    RIDGEFIELD, Conn. — Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

    Lilly and BI, which recently launched the oral diabetes drug Tradjenta (linagliptin) will present data from studies of the drug, as well as studies on BI-10773, an investigational diabetes drug made by BI.

  • CVS/pharmacy introduces CARE 1on1

    WOONSOCKET, R.I. — CVS/pharmacy has introduced its latest initiative, designed to underscore the role pharmacists play in managing ongoing medications for chronic illnesses, particularly when a patient starts a new medication.

  • Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

    Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


  • CVS fights disease in ethnic communities

    CVS/pharmacy spent the last couple of months sponsoring nearly 300 free screening and consultation events in Atlanta, Washington, D.C., and Philadelphia targeting African-American communities. 


    Part of the chain’s To Your Health program, the events were an extension of the A Su Salud events targeting Hispanic customers in Los Angeles, Dallas, Houston and Miami. To Your Health started in Atlanta on April 17, moving on to Washington, D.C., on June 12 and Philadelphia on June 19.


  • FDA updates ongoing safety review of Actos

    SILVER SPRING, Md. — The Food and Drug Administration on Thursday informed the public that continued use of a Type 2 diabetes treatment made by Takeda Pharmaceuticals for more than one year may be associated with an increased risk of bladder cancer.

  • Nipro, NeuroMetrix collaborate to market NC-stat DPNCheck

    WALTHAM, Mass. — Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.

    Nipro and NeuroMetrix said the NC-stat DPNCheck test, developed by NeuroMetrix, could offer a cost-effective approach to detecting and monitoring DPN, which affects more than half of people with diabetes and could lead to such conditions as foot ulcers and limb amputation.

    The companies currently are evaluating opportunities for the NC-stat DPNCheck in retail medical clinics.

  • Liraglutide may prompt optimal blood-glucose levels in Type 1 diabetics

    BUFFALO, N.Y. — A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

X
This ad will auto-close in 10 seconds